logo-loader
viewPropanc Biopharma, Inc.

Propanc at final stages of completing manufacturing steps to file first clinical trial application

Propanc Biopharma, Inc. (OTCQB: PPCB) CEO James Nathanielsz sat down with Proactive Investors at the BIO CEO and Investor Conference in New York.

The biopharmaceutical company is developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers.

Quick facts: Propanc Biopharma, Inc.

Price: 0.07 USD

OTCMKTS:PPCB
Market: OTCQB
Market Cap: $245.11 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Technology Metals discusses plans for 2020 and beyond

Technology Metals Ltd (ASX:TMT) executive director Ian Prentice speaks to Proactive about its plans for 2020 and beyond. The company’s Gabanintha Vanadium Project has recently been selected for Lead Agency support by the WA State Government, marking an important milestone for the project’s...

2 hours, 16 minutes ago

2 min read